<DOC>
	<DOCNO>NCT02817113</DOCNO>
	<brief_summary>NC-6004 polymeric micelle contain cisplatin active moiety . The nanoparticle provide sustained release active moiety utilizes enhance permeability retention ( EPR ) effect target release platinum tumor . This Phase I study aim establish recommend dose ( RD ) triplet combination NC-6004 plus 5-FU cetuximab first-line treatment patient recurrent and/or metastatic squamous cell carcinoma head neck clinical study development .</brief_summary>
	<brief_title>Study NC-6004 Combination With 5-FU Cetuximab Patients With Head Neck Cancer</brief_title>
	<detailed_description>1 . Primary objective ♦ To determine Maximum Tolerated Dose ( MTD ) NC-6004 accord Dose Limiting Toxicity ( DLT ) combination 5-FU plus cetuximab firstline treatment patient recurrent and/or metastatic squamous cell carcinoma head neck ( SCCHN ) , decide RD follow study 2 . Secondary objective 1 ) . To evaluate safety tolerability profile NC-6004 combination 5- FU plus cetuximab 2 ) . To assess pharmacokinetic effect NC-6004 3 ) . To assess antitumor effect NC-6004</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Signed write informed consent Known ( histology/cytology proven ) evidence radiology recurrent and/or metastatic SCCHN suit local therapy Males female age ≥ 20 year &lt; 75 year Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Life expectancy &gt; 12 week judge investigator Adequate bone marrow reservation : Adequate liver function : Adequate renal function : Reasonably recover precede major surgery judge Investigator major surgery within 4 week prior start Day 1 treatment Female childbearing potential intention pregnant breastfeeding . Previous radiotherapy within 3 month study entry Known brain metastasis leptomeningeal involvement Marked pleural effusion ascites Grade 2 , base NCICTCAE v4.03 criterion History thrombocytopenia complication ( include hemorrhage bleeding ≥ Grade 2 , base NCICTCAE v4.03 criterion ) , hemolytic condition , coagulation disorder would make subject unsafe base judgment Investigator Patients unresolved toxicity radiation , adjuvant/neoadjuvant chemotherapy , target treatment include investigational treatment ( exception alopecia ≤ Grade 2 peripheral neuropathy ) accord NCICTCAE v4.03 criterion Known hypersensitivity study drug drug similar chemical structure History myocardial infarction within 6 month study entry , unstable congestive heart failure ( New York Heart Association , NYHA Stage IIIIV ) , angina pectoris , transient ischemic attack cardiac arrhythmia require medical therapy History cancer head neck cancer ( HNC ) ( except carcinoma situ cervix ) within last 5 year . Primary tumor nasopharynx ( nasopharyngeal carcinoma ) Known HIV1 active infection require IV antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>